MYC and plasma cell myeloma: JQ1(+) has been identified to be a promising cancer therapeutic, having been shown to prevent BRD4, a BET family protein, from interacting with and recruiting Myc, a transcription factor involved in cell proliferation that has been found to be constitutively active in several cancers, such as acute myeloid leukemia and multiple myeloma (42, 43).